Kymera Therapeutics, Inc. Balance Sheet
KYMR / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$1.7B
FY2025
Cash
$357M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$1.6B
FY2025
Kymera Therapeutics, Inc. had $1.7B in total assets and $1.6B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $31.0M | $76.0M | $76.0M |
| Accounts Receivable | - | $0 | $15.0M | $0 | - | - | - |
| Current Assets | $871.2M | $510.3M | $405.3M | $419.4M | $451.3M | $302.3M | $92.8M |
| PP&E (Net) | $43.2M | $50.5M | $48.1M | $13.3M | $11.9M | $10.8M | $3.8M |
| Total Assets | $1.7B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M | $116.7M |
| Current Liabilities | $83.2M | $67.8M | $85.7M | $71.3M | $92.5M | $110.6M | $34.6M |
| Shareholders' Equity | $1.6B | $835.6M | $395.0M | $490.2M | -$74.4M | -$34.4M | -$74.4M |